Bio-Techne Corp (NASDAQ:TECH) is reporting first quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, TECH is expected to report 1Q21 income of $ 1.09 per share from revenue of $ 185.03 million.
For the full year, analysts anticipate top line of $ 824.22 million, while looking forward to income of $ 5.44 per share bottom line.
Previous Quarter Performance
Bio-Techne Corp came out with income for the fourth quarter of $ 1.00 per share, from the revenue of $ 175.83 million. The quarterly earnings decreased 20.00 percent while revenues reduced 8.26 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.75 per share from $ 163.91 million in revenue. The bottom line results beat street analysts by $ 0.25 or 33.33 percent, at the same time, top line results outshined analysts by $ 11.92 million or 7.27 percent.
Stock Performance
Shares of Bio-Techne Corp traded up $ 0.82 or 0.31 percent on Wednesday, reaching $ 267.16 with volume of 215.40 thousand shares. Bio-Techne Corp has traded high as $ 277.10 and has cracked $ 264.05 on the downward trend
The closing price of $ 267.16, representing a 71.64 % increase from the 52 week low of $ 155.17 and a 7.1 % decrease over the 52 week high of $ 286.68.
The company has a market capital of $ 10.30 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Stock Dividend Announcement
On August 4, 2020, the board of directors authorized quarterly dividend of $ 0.32 per share to holders of record as of the close of business on August 18, 2020, with payment date of August 28, 2020 and ex-dividend date on August 17, 2020.
Conference Call
Bio-Techne Corp will be hosting a conference call at 9:00 AM eastern time on 5th November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.bio-techne.com
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
